Laboratory Medicine ›› 2015, Vol. 30 ›› Issue (9): 968-970.DOI: 10.3969/j.issn.1673-8640.2015.09.023
• Orginal Article • Previous Articles
Received:
2015-02-28
Online:
2015-09-30
Published:
2015-09-29
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2015.09.023
组别 | 例数 | Lp-PLA2 (mg/L) | TC (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | D-D(ng/mL) |
---|---|---|---|---|---|---|---|
正常对照组 | 62 | 128.78±46.22 | 4.72±0.67 | 1.37±0.78 | 1.34±0.22 | 2.11±0.98 | 455.8(202.3,608.9) |
ACI组 | 89 | 268.65±89.02 | 4.81±0.78 | 2.02±0.97 | 1.29±0.18 | 3.59±0.79 | 809.7(623.7,946.0) |
统计值 | t=11.418 | t=0.743 | t=4.410 | t=1.543 | t=10.32 | Z=-7.676 | |
P值 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | <0.01 |
组别 | 例数 | Lp-PLA2 (mg/L) | TC (mmol/L) | TG (mmol/L) | HDL-C (mmol/L) | LDL-C (mmol/L) | D-D(ng/mL) |
---|---|---|---|---|---|---|---|
正常对照组 | 62 | 128.78±46.22 | 4.72±0.67 | 1.37±0.78 | 1.34±0.22 | 2.11±0.98 | 455.8(202.3,608.9) |
ACI组 | 89 | 268.65±89.02 | 4.81±0.78 | 2.02±0.97 | 1.29±0.18 | 3.59±0.79 | 809.7(623.7,946.0) |
统计值 | t=11.418 | t=0.743 | t=4.410 | t=1.543 | t=10.32 | Z=-7.676 | |
P值 | <0.01 | >0.05 | <0.01 | >0.05 | <0.01 | <0.01 |
组别 | 例数 | CIMT(mm) | Lp-PLA2(mg/L) | D-D(ng/mL) |
---|---|---|---|---|
无斑块组 | 18 | 0.89±0.27 | 137.56±55.57 | 465.78±277.62 |
稳定斑块组 | 33 | 1.38±0.22* | 198.67±57.25* | 876.24±445.87* |
不稳定斑块组 | 38 | 1.41±0.32* | 288.89±79.72*# | 1 011.45±578.52*# |
组别 | 例数 | CIMT(mm) | Lp-PLA2(mg/L) | D-D(ng/mL) |
---|---|---|---|---|
无斑块组 | 18 | 0.89±0.27 | 137.56±55.57 | 465.78±277.62 |
稳定斑块组 | 33 | 1.38±0.22* | 198.67±57.25* | 876.24±445.87* |
不稳定斑块组 | 38 | 1.41±0.32* | 288.89±79.72*# | 1 011.45±578.52*# |
[1] | 何德化,李卫华. 脂蛋白相关磷脂酶A2与冠心病的相关性研究进展[J]. 心血管病学进展,2008,29(1):57-60. |
[2] | KOLODGIE FD, BURKE AP, SKORIJA KS, et al.Lipoprotein-associated phosphoipase A2 protein expression in the natural progression of human coronary atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2006,26(11):2523-2529. |
[3] | 陈峻,马涛,崔天盆. 急性脑梗死患者血浆FDP、D-D和CRP联合检测的临床价值[J]. 标记免疫分析与临床,2013,20(2):111-112. |
[4] | 中华医学会全国第四届脑血管病学术会议. 各类脑血管疾病诊断要点[J]. 中华神经科杂志,1996,42(6):60-61. |
[5] | 贵永堃,吕晓红. 脂蛋白相关磷脂酶A2与缺血性脑血管疾病的研究进展[J]. 中风与神经疾病杂志,2011,28(1):86-88. |
[6] | 龙璐,王钟明,陈贞,等. 急性缺血性脑卒中患者血浆Lp-PLA2水平与颈动脉硬化斑块稳定性及神经功能缺损程度的关系[J]. 检验医学,2013,28(10):885-889. |
[7] | 叶芸,李苏亮. 脑卒中患者血浆Lp-PLA2水平及临床意义探讨[J]. 检验医学,2014,29(3):249-253. |
[8] | 陈新民,陈福民.急性缺血性脑卒中患者颈动脉粥样硬化与D-二聚体水平的关系[J].中国医药导刊,2013,15(5):872. |
[9] | 王慧. 急性脑梗死患者NSE、hs-CRP和D-二聚体检测的临床意义[J]. 中国现代医生,2014,8(21):67-69. |
[10] | SMITH A,PATTERSON C,YARNELL J,et al.Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study[J]. Circulation,2005,112(20):3080-3087. |
[11] | VOROBEVA NM,PANCHENKO EP,DOBROVOLSKII AB,et al.Elevated D-dimer in patients with cardiovascular diseases free from thromboembolic complications: what is it associated with and what has to be done[J]. Angiol Sosud Khir,2010,16(4):34-41. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||